Fundacio Puigvert — Clinical Trial Site

54 Registered trials

27 Currently recruiting

Organisation

Fundacio Puigvert

Location

Barcelona, Spain

Identifier

ORG-100032773

Address

Cartagena 340-350, 8025, Spain

Departments

#3275:Urologia
Department of Nephrology
Department of Urology
Medical Oncology
Nefrología
Nefrología y Trasplante Renal
Nephrologist
Nephrology
Nephrology Department
Nephrology Service
None
Obstetricia y Ginecología
Oncologia
Oncology-Urology Unit
Servicio de Nefrología
Servicio de Urologia
Trasplante Renal
Urologia
Urology

Clinical trials at this site (54)

Search interface

A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca… Recruiting

2024-511775-15-00 Immune system diseases 4 2025-01-17
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617… Recruiting

2022-502956-29-00 Oligometastatic prostate cancer (OMPC) 5 2024-07-01
HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting

2022-500210-26-00 Autosomal Dominant Polycystic Kidney Disease (ADPKD) 5 2024-06-28
A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppressio… Recruiting

2023-506879-98-00 Renal transplantation 6 2024-01-22
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting

2024-513562-19-00 End-Stage Kidney Disease 5 2023-08-30
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN). Recruiting

2023-507233-19-00 Treatment of IgAN 10 2023-02-16
Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients Ended

2024-519978-39-00 Kidney trasplants 3 2026-04-17
A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended

2024-517143-31-00 Autosomal Dominant Polycystic Kidney Disease 4 2025-07-18
A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC. Ended

2023-507261-25-00 Nonmuscle Invasive Bladder Cancer 5 2024-10-03
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves… Ended

2023-507685-10-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2024-05-30
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin… Ended

2024-518486-10-00 Non-Muscle Invasive Bladder Cancer 4 2023-02-23
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended

2023-504597-37-00 Focal segmental glomerulosclerosis 5 2022-03-25
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of … Ended

2024-513227-16-00 Immunoglobulin A Nephropathy (IgAN) 5 2021-05-19
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M… Ended

2023-507188-21-00 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Blad 5 2021-04-20
CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi… Ended

2023-509089-39-00 Non-Muscle Invasive Bladder Cancer 5 2020-07-01
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended

2022-501817-29-00 High Risk Non-muscle invasive bladder cancer 5 2018-11-27
Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos… Ended

2023-505341-23-00 Non-muscle invasive bladder cancer 5 2018-07-27
A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants w… Halted

2024-516095-15-00 Kidney Disease 1 2025-08-05
Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome Ended

2023-509638-20-00 Alport Syndrome 4 2024-09-30
A Phase 2a Study to Evaluate Setanaxib in Patients with Alport Syndrome Ended

2023-505292-73-00 Alport syndrome 4 2024-01-10